ViroCell Biologics Supports UCL Clinical Trial with High-Yield Lentiviral Vector

• ViroCell Biologics is supplying the lentiviral vector for a University College London clinical trial targeting relapsed paediatric acute lymphoblastic leukaemia (ALL).

• The Phase I trial, led by Professor Persis Amrolia, began enrolling patients in March 2025.

ViroCell Biologics, a specialist viral vector CDMO for cell and gene therapy clinical trials, is supporting a newly launched clinical study at University College London (UCL). The trial, known as CARPALL (cohort 4), is investigating a next-generation CAR T-cell therapy for relapsed paediatric acute lymphoblastic leukaemia (ALL).

The study, which began patient enrolment in March 2025, is led by Professor Persis Amrolia of UCL’s Great Ormond Street Institute of Child Health. The trial seeks to improve upon current CAR T-cell treatments by targeting both CD19 and CD22 antigens, while preserving stem cell memory T-cells to enhance therapeutic persistence and reduce relapse risk.

ViroCell was selected to manufacture the lentiviral vector used in this investigational treatment, based on its proven expertise in delivering high-quality, high-yield viral vectors. This supports UCL and Great Ormond Street Hospital’s research efforts by enabling efficient progression from design to manufacturing.

“We are honoured to support such prestigious research institutions as GOSH and UCL to bring next-generation CAR T-cells to paediatric patients with relapsed acute lymphoblastic leukaemia,” said Farzin Farzaneh, PhD, Chief Scientific Officer at ViroCell.